Literature DB >> 9583930

Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.

N Freemantle, J Mason.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9583930

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Medicalisation, limits to medicine, or never enough money to go around?

Authors:  Nick Freemantle; Suzanne Hill
Journal:  BMJ       Date:  2002-04-13

Review 2.  Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Authors:  A J Coukell; M I Wilde
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.